Answers are grounded in this paper and cite their sources.
Pre-clinical studies demonstrate enhanced safety and efficacy of car-nk/t cells in haematological cancers, suggesting a flexible alternative to car-t cells.
I get a message the abstract is missing, but it IS here!!!!! Background: Chimeric Antigen Receptor (CAR)-NK/T-cells offer a new approach in immune therapy of haematological cancers. NK/T-cells bridge innate and adaptive immunity with strong anti-cancer effects. Unlike allogeneic CAR-T-cells, CAR-NK/T-cells do not require TCR genetic deletion to prevent major MHC recognition, have a lower risk of graft-versus-host disease (GvHD), and can be used universally. Summary: Pre-clinical studies report CAR-NK/T-cells effectively target antigens such as CD19 and BCMA in B-cell lymphomas and plasma cell myeloma (PCM). Compared with CAR-T-cells, CAR-NK/T-cells have faster immune responses, more cytotoxicity and better safety. Recent innovations increase efficacy of CAR-NK/T-cell therapies. Early clinical trials report promising safety and efficacy. Although still in the early phases of development advances in NK/T-cell therapy are overcoming prior challenges. Key Messages: CAR-NK/T-cells may prove a safer, more flexible form of cell therapy of haematological cancers.
No takes yet. Share an insight, caveat, or question.
Noorafrooz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: